Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.44 USD | -0.90% |
|
-4.20% | +0.80% |
06-11 | Japan's Nikkei rises on US stocks, heavyweight chip shares | RE |
05-28 | Terumo Cardiovascular Announces 510(K) Clearance for the CDI Oneview?? Monitoring System | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company is in a robust financial situation considering its net cash and margin position.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 36.21 times its estimated earnings per share for the ongoing year.
- The company's enterprise value to sales, at 4.33 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+0.80% | 24.77B | - | ||
-5.81% | 180B | C+ | ||
-1.63% | 106B | C | ||
-4.14% | 67.55B | A | ||
-6.56% | 46.11B | B- | ||
+13.22% | 45.79B | B- | ||
+6.13% | 41.61B | B+ | ||
+19.93% | 31.07B | B | ||
-5.36% | 24.27B | A- | ||
-11.92% | 22.05B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 4543 Stock
- TRUMY Stock
- Ratings Terumo Corporation